pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1208 |
Genomic Coordinates | chr8: 128150116 - 128150188 |
Synonyms | MIRN1208, hsa-mir-1208, MIR1208 |
Description | Homo sapiens miR-1208 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1208 | |||||||||||||||||||||||||||
Sequence | 12| UCACUGUUCAGACAGGCGGA |31 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Northern | |||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | MAPK14 | ||||||||||||||||||||
Synonyms | CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2, PRKM14, PRKM15, RK, SAPK2A, p38, p38ALPHA | ||||||||||||||||||||
Description | mitogen-activated protein kinase 14 | ||||||||||||||||||||
Transcript | NM_139014 | ||||||||||||||||||||
Other Transcripts | NM_139012 , NM_139013 , NM_001315 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on MAPK14 | |||||||||||||||||||||
3'UTR of MAPK14 (miRNA target sites are highlighted) |
>MAPK14|NM_139014|3'UTR 1 ATGAGTGGAAAAGCCTGACCTATGATGAAGTCATCAGCTTTGTGCCACCACCCCTTGACCAAGAAGAGATGGAGTCCTGA 81 GCACCTGGTTTCTGTTCTGTTGATCCCACTTCACTGTGAGGGGAAGGCCTTTTCACGGGAACTCTCCAAATATTATTCAA 161 GTGCCTCTTGTTGCAGAGATTTCCTCCATGGTGGAAGGGGGTGTGCGTGCGTGTGCGTGCGTGTTAGTGTGTGTGCATGT 241 GTGTGTCTGTCTTTGTGGGAGGGTAAGACAATATGAACAAACTATGATCACAGTGACTTTACAGGAGGTTGTGGATGCTC 321 CAGGGCAGCCTCCACCTTGCTCTTCTTTCTGAGAGTTGGCTCAGGCAGACAAGAGCTGCTGTCCTTTTAGGAATATGTTC 401 AATGCAAAGTAAAAAAATATGAATTGTCCCCAATCCCGGTCATGCTTTTGCCACTTTGGCTTCTCCTGTGACCCCACCTT 481 GACGGTGGGGCGTAGACTTGACAACATCCCACAGTGGCACGGAGAGAAGGCCCATACCTTCTGGTTGCTTCAGACCTGAC 561 ACCGTCCCTCAGTGATACGTACAGCCAAAAAGGACCAACTGGCTTCTGTGCACTAGCCTGTGATTAACTTGCTTAGTATG 641 GTTCTCAGATCTTGACAGTATATTTGAAACTGTAAATATGTTTGTGCCTTAAAAGGAGAGAAGAAAGTGTAGATAGTTAA 721 AAGACTGCAGCTGCTGAAGTTCTGAGCCGGGCAAGTCGAGAGGGCTGTTGGACAGCTGCTTGTGGGCCCGGAGTAATCAG 801 GCAGCCTTCATAGGCGGTCATGTGTGCATGTGAGCACATGCGTATATGTGCGTCTCTCTTTCTCCCTCACCCCCAGGTGT 881 TGCCATTTCTCTGCTTACCCTTCACCTTTGGTGCAGAGGTTTCTTGAATATCTGCCCCAGTAGTCAGAAGCAGGTTCTTG 961 ATGTCATGTACTTCCTGTGTACTCTTTATTTCTAGCAGAGTGAGGATGTGTTTTGCACGTCTTGCTATTTGAGCATGCAC 1041 AGCTGCTTGTCCTGCTCTCTTCAGGAGGCCCTGGTGTCAGGCAGGTTTGCCAGTGAAGACTTCTTGGGTAGTTTAGATCC 1121 CATGTCACCTCAGCTGATATTATGGCAAGTGATATCACCTCTCTTCAGCCCCTAGTGCTATTCTGTGTTGAACACAATTG 1201 ATACTTCAGGTGCTTTTGATGTGAAAATCATGAAAAGAGGAACAGGTGGATGTATAGCATTTTTATTCATGCCATCTGTT 1281 TTCAACCAACTATTTTTGAGGAATTATCATGGGAAAAGACCAGGGCTTTTCCCAGGAATATCCCAAACTTCGGAAACAAG 1361 TTATTCTCTTCACTCCCAATAACTAATGCTAAGAAATGCTGAAAATCAAAGTAAAAAATTAAAGCCCATAAGGCCAGAAA 1441 CTCCTTTTGCTGTCTTTCTCTAAATATGATTACTTTAAAATAAAAAAGTAACAAGGTGTCTTTTCCACTCCTATGGAAAA 1521 GGGTCTTCTTGGCAGCTTAACATTGACTTCTTGGTTTGGGGAGAAATAAATTTTGTTTCAGAATTTTGTATATTGTAGGA 1601 ATCCTTTGAGAATGTGATTCCTTTTGATGGGGAGAAAGGGCAAATTATTTTAATATTTTGTATTTTCAACTTTATAAAGA 1681 TAAAATATCCTCAGGGGTGGAGAAGTGTCGTTTTCATAACTTGCTGAATTTCAGGCATTTTGTTCTACATGAGGACTCAT 1761 ATATTTAAGCCTTTTGTGTAATAAGAAAGTATAAAGTCACTTCCAGTGTTGGCTGTGTGACAGAATCTTGTATTTGGGCC 1841 AAGGTGTTTCCATTTCTCAATCAGTGCAGTGATACATGTACTCCAGAGGGACAGGGTGGACCCCCTGAGTCAACTGGAGC 1921 AAGAAGGAAGGAGGCAGACTGATGGCGATTCCCTCTCACCCGGGACTCTCCCCCTTTCAAGGAAAGTGAACCTTTAAAGT 2001 AAAGGCCTCATCTCCTTTATTGCAGTTCAAATCCTCACCATCCACAGCAAGATGAATTTTATCAGCCATGTTTGGTTGTA 2081 AATGCTCGTGTGATTTCCTACAGAAATACTGCTCTGAATATTTTGTAATAAAGGTCTTTGCACATGTGACCACATACGTG 2161 TTAGGAGGCTGCATGCTCTGGAAGCCTGGACTCTAAGCTGGAGCTCTTGGAAGAGCTCTTCGGTTTCTGAGCATAATGCT 2241 CCCATCTCCTGATTTCTCTGAACAGAAAACAAAAGAGAGAATGAGGGAAATTGCTATTTTATTTGTATTCATGAACTTGG 2321 CTGTAATCAGTTATGCCGTATAGGATGTCAGACAATACCACTGGTTAAAATAAAGCCTATTTTTCAAATTTAGTGAGTTT 2401 CTCAAGTTTATTATATTTTTCTCTTGTTTTTATTTAATGCACAATATGGCATTATATCAATATCCTTTAAACTGTGACCT 2481 GGCATACTTGTCTGACAGATCTTAATACTACTCCTAACATTTAGAAAATGTTGATAAAGCTTCTTAGTTGTACATTTTTT 2561 GGTGAAGAGTATCCAGGTCTTTGCTGTGGATGGGTAAAGCAAAGAGCAAATGAACGAAGTATTAAGCATTGGGGCCTGTC 2641 TTATCTACACTCGAGTGTAAGAGTGGCCGAAATGACAGGGCTCAGCAGACTGTGGCCTGAGGGCCAAATCTGGCCCACCA 2721 CCTGTTTGGTGTAGCCTGCTAAGAATGGCTTTTACATTTTTAAATGGTTGGGAAAGAAAAAAAAAGAAGTAGTAGATTTT 2801 GTAGCATGTGATGTAAGTAATGTAAAACTTAAATTCCAGTATCCATAAATAAAGTTTTATGAGAACAGA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | hESCs (WA-09) | ||||||
Disease | 1432.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
CLIP-seq Support 1 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000229795.3 | 3UTR | UGUGCUACAGUGACAGAGGCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
55 hsa-miR-1208 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT076103 | ADORA2B | adenosine A2b receptor | 2 | 2 | ||||||||
MIRT447464 | OSMR | oncostatin M receptor | 2 | 2 | ||||||||
MIRT448145 | ESF1 | ESF1 nucleolar pre-rRNA processing protein homolog | 2 | 2 | ||||||||
MIRT463639 | YY1 | YY1 transcription factor | 2 | 4 | ||||||||
MIRT465065 | TSR1 | TSR1, ribosome maturation factor | 2 | 2 | ||||||||
MIRT468464 | SET | SET nuclear proto-oncogene | 2 | 4 | ||||||||
MIRT480171 | CALM3 | calmodulin 3 | 2 | 2 | ||||||||
MIRT481495 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 2 | 8 | ||||||||
MIRT484111 | ABCD2 | ATP binding cassette subfamily D member 2 | 2 | 4 | ||||||||
MIRT499834 | PCSK9 | proprotein convertase subtilisin/kexin type 9 | 2 | 8 | ||||||||
MIRT500261 | ZNF788 | zinc finger family member 788 | 2 | 6 | ||||||||
MIRT500551 | XBP1P1 | X-box binding protein 1 pseudogene 1 | 2 | 8 | ||||||||
MIRT502697 | CSNK1G1 | casein kinase 1 gamma 1 | 2 | 4 | ||||||||
MIRT517786 | EFCAB11 | EF-hand calcium binding domain 11 | 2 | 2 | ||||||||
MIRT519191 | IVD | isovaleryl-CoA dehydrogenase | 2 | 2 | ||||||||
MIRT523114 | HSPA4L | heat shock protein family A (Hsp70) member 4 like | 2 | 2 | ||||||||
MIRT527425 | NRL | neural retina leucine zipper | 2 | 2 | ||||||||
MIRT529509 | IYD | iodotyrosine deiodinase | 2 | 2 | ||||||||
MIRT533705 | TMEM67 | transmembrane protein 67 | 2 | 2 | ||||||||
MIRT535694 | NEURL1B | neuralized E3 ubiquitin protein ligase 1B | 2 | 2 | ||||||||
MIRT536141 | MAPK14 | mitogen-activated protein kinase 14 | 2 | 2 | ||||||||
MIRT544878 | ZNF543 | zinc finger protein 543 | 2 | 4 | ||||||||
MIRT551362 | EPM2AIP1 | EPM2A interacting protein 1 | 2 | 2 | ||||||||
MIRT555949 | NUCKS1 | nuclear casein kinase and cyclin dependent kinase substrate 1 | 2 | 2 | ||||||||
MIRT561498 | SRSF2 | serine and arginine rich splicing factor 2 | 2 | 2 | ||||||||
MIRT569681 | AMACR | alpha-methylacyl-CoA racemase | 2 | 2 | ||||||||
MIRT572518 | KIAA0232 | KIAA0232 | 2 | 2 | ||||||||
MIRT572877 | OPHN1 | oligophrenin 1 | 2 | 2 | ||||||||
MIRT572924 | PRAMEF1 | PRAME family member 1 | 2 | 2 | ||||||||
MIRT607528 | ABL2 | ABL proto-oncogene 2, non-receptor tyrosine kinase | 2 | 2 | ||||||||
MIRT611076 | ZNF621 | zinc finger protein 621 | 2 | 2 | ||||||||
MIRT613236 | CCDC39 | coiled-coil domain containing 39 | 2 | 2 | ||||||||
MIRT616542 | NFATC2 | nuclear factor of activated T-cells 2 | 2 | 2 | ||||||||
MIRT620010 | CCDC137 | coiled-coil domain containing 137 | 2 | 2 | ||||||||
MIRT621491 | STYK1 | serine/threonine/tyrosine kinase 1 | 2 | 2 | ||||||||
MIRT622379 | SALL1 | spalt like transcription factor 1 | 2 | 2 | ||||||||
MIRT628226 | FBXL20 | F-box and leucine rich repeat protein 20 | 2 | 2 | ||||||||
MIRT636458 | LRCH3 | leucine rich repeats and calponin homology domain containing 3 | 2 | 2 | ||||||||
MIRT636546 | FAM126B | family with sequence similarity 126 member B | 2 | 2 | ||||||||
MIRT637350 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | 2 | 2 | ||||||||
MIRT637604 | ZNF554 | zinc finger protein 554 | 2 | 2 | ||||||||
MIRT637732 | EXO5 | exonuclease 5 | 2 | 2 | ||||||||
MIRT638697 | GABRB1 | gamma-aminobutyric acid type A receptor beta1 subunit | 2 | 2 | ||||||||
MIRT640634 | ZIC4 | Zic family member 4 | 2 | 2 | ||||||||
MIRT641535 | SNW1 | SNW domain containing 1 | 2 | 2 | ||||||||
MIRT648796 | VPS8 | VPS8, CORVET complex subunit | 2 | 2 | ||||||||
MIRT663060 | LRIF1 | ligand dependent nuclear receptor interacting factor 1 | 2 | 2 | ||||||||
MIRT666581 | RHOBTB3 | Rho related BTB domain containing 3 | 2 | 2 | ||||||||
MIRT699206 | FYN | FYN proto-oncogene, Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT704875 | CD164 | CD164 molecule | 2 | 2 | ||||||||
MIRT706850 | DNAJB13 | DnaJ heat shock protein family (Hsp40) member B13 | 2 | 2 | ||||||||
MIRT712941 | CCBE1 | collagen and calcium binding EGF domains 1 | 2 | 3 | ||||||||
MIRT714653 | FSTL1 | follistatin like 1 | 2 | 2 | ||||||||
MIRT722320 | SH2D1A | SH2 domain containing 1A | 2 | 2 | ||||||||
MIRT722535 | EPRS | glutamyl-prolyl-tRNA synthetase | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|